We are presenting the results of our research at the European Society for Medical Oncology (ESMO)

Celon Pharma S.A. will present the results of its research on innovative kinase inhibitors at the European Society for Medical Oncology (ESMO) Congress which will be held in Madrid on 26-30 September 2014. We encourage participants of the Congress to examine our poster entitled: “Preclinical evaluation of a novel, selective pan-FGFR kinase inhibitor CPL-304-110 as a potential anticancer targeted therapy”.